Drugs / Human embryonic stem cell-derived CD15+ Isl-1+ progenitors
Human embryonic stem cell-derived CD15+ Isl-1+ progenitors
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02057900 | May 2013 → Mar 2018 | ischemic disease | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human embryonic stem cell-derived CD15+ Isl-1+ progenitors | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02057900 ↗ |
| Modality | Cell therapy | “cardiac-committed progenitor cells derived from human embryonic stem cells” NCT02057900 ↗ |
| Route | Other | “Epicardial delivery of a fibrin patch embedding human embryonic stem cell-derived CD15+ Isl-1+ progenitors” NCT02057900 ↗ |